Today: 20 May 2026
Celsius Stock Near 52-Week Low Before Q1 Earnings as PepsiCo Energy Bet Faces Test
6 May 2026
2 mins read

Celsius Stock Near 52-Week Low Before Q1 Earnings as PepsiCo Energy Bet Faces Test

BOCA RATON, Florida, May 6, 2026, 4:03 PM EDT

Shares of Celsius Holdings slipped on Wednesday, trading near their lowest levels in a year as the market braced for Thursday’s Q1 report. Investors are looking for any evidence that the PepsiCo deal can turn recent buyouts into steady gains. Earnings drop before the bell, with a webcast set for 8 a.m. ET.

Timing matters. Celsius isn’t only the energy drink anymore; now it manages CELSIUS, Alani Nu, and Rockstar Energy in the U.S. and Canada, all under PepsiCo’s distribution. So Thursday’s report does more than track sales trends—it gives a read on how Celsius has handled realignment in distribution and brought fresh brands into the fold over the last year.

Rothschild Redburn’s Charlie Higgs initiated coverage on Celsius with a Neutral rating this Wednesday, StreetInsider reported. The firm set a price target of $47, per Investing.com. Shares of Celsius hovered around $33, brushing against a 52-week low—well off the mark from where a number of analysts remain bullish.

Wall Street expects first-quarter revenue to reach $755.2 million, a 129.4% surge from a year ago, according to Zacks-compiled estimates. Earnings per share are forecast at 29 cents, up 61.1%. That’s a tall order, especially since CELSIUS’s gains lately have leaned on Alani Nu and Rockstar alongside its flagship label.

Celsius turned in fourth-quarter revenue of $721.6 million, surging 117% from a year ago. For all of 2025, revenue climbed 85.5% to $2.52 billion. CEO John Fieldly called 2025 “a defining year.” Still, not everything pushed higher: CELSIUS brand sales edged down in Q4, while Alani Nu set a new record and Rockstar tacked on $45 million. Celsius Holdings

Earlier, the company said it wanted Alani Nu’s integration wrapped up by the end of Q1, and Rockstar coming in Q2. That puts a spotlight on management’s commentary around shipments, shelf resets, margins. One note: when they talk about a stock-keeping unit, or SKU, they mean any individual product variant—think a particular flavor or package. Changes in SKUs can push sales between sales channels or bump numbers from one quarter to another.

PepsiCo is right in the thick of it. In August, the company put down $585 million for new Celsius preferred shares, lifting its stake to roughly 11% as converted. Around the same time, Celsius grabbed control of Rockstar Energy’s business across the U.S. and Canada. “Energy is an important growth category,” said Ram Krishnan, chief of PepsiCo Beverages U.S., back then. Business Wire

Celsius crept deeper into the Red Bull and Monster Beverage orbit after the move. Reuters reported that, with PepsiCo in its corner, Celsius and PepsiCo together grabbed about 20% of the energy-drink market last year. Keurig Dr Pepper, for its part, countered with a Ghost partnership, throwing fresh cash into the energy drink battle for share.

Short-term numbers could get messy. Investors, per Investing.com, are focused on Costco’s lower-priced Kirkland Signature energy drink, SKU reductions, tweaks to shelf placement, and higher aluminum costs. Jefferies trimmed its price target on Celsius to $67 from $71 this week—still a Buy—but warned that Alani Nu’s switch could blur this quarter’s picture.

Celsius shares lost 2.8%, settling at $32.59, leaving the company with an $8.4 billion market cap. Investors are watching Thursday’s report closely; it’s shaping up as a test of whether this recent dip is just a breather, or early evidence that momentum from the PepsiCo distribution deal remains sluggish.

Stock Market Today

  • FS KKR Capital Corp Offers 15.3% Yield Amid Dividend Cuts and $600M Management Buy-In
    May 20, 2026, 10:08 AM EDT. FS KKR Capital Corp (FSK) presents a compelling 15.3% yield despite recent two consecutive dividend cuts, drawing investor interest due to management's strategic response. The firm, a business development company (BDC) managed by KKR, is facing credit challenges from struggling middle-market borrowers amid rising interest rates, with non-accrual loans increasing to 4.2%. FSK shares trade at 58 cents on the dollar, significantly below book value, reflecting market pessimism. In response, KKR is investing $600 million to support the stock, including purchasing $150 million in preferred shares convertible at net asset value (NAV). This capital infusion aims to shrink the valuation discount and boost share buybacks, indicating potential price appreciation as credit conditions stabilize.

Latest articles

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

20 May 2026
Vida Global Inc. raised $15 million in its May 18 IPO, selling 3.75 million shares at $4 each, but the stock closed at $2.29 on Tuesday. CEO Lyle Pratt bought 312,900 shares for about $1.19 million, according to a Form 4 filing. Vida reported 2025 revenue of $551,383 and a net loss of $2.9 million. The company’s shares trade on NYSE American and NYSE Texas under the symbol VIDA.
TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

20 May 2026
TJX raised its fiscal 2027 sales, earnings, and buyback targets after first-quarter comparable sales rose 6% and net income hit $1.3 billion. Shares climbed 3.6% in premarket trading. The company cited higher fuel costs as a drag on its full-year forecast. Marmaxx, HomeGoods, and TJX Canada all posted strong sales growth.
ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

ImmunityBio Faces FDA Decision on Bladder-Cancer Application, Risk Remains

20 May 2026
The FDA accepted ImmunityBio’s application to expand Anktiva’s use with BCG in papillary-only, BCG-unresponsive non-muscle invasive bladder cancer, setting a Jan. 6, 2027 decision date. ImmunityBio reported $44.2 million in first-quarter net product revenue and held $380.9 million in cash and equivalents. Shares last traded at $7.76, down 2.8%. The filing is supported by data from 80 patients in a Phase 2/3 trial.
Beyond Meat Stock Reclaims $1 Before BYND Earnings, But Nasdaq Pressure Remains
Previous Story

Beyond Meat Stock Reclaims $1 Before BYND Earnings, But Nasdaq Pressure Remains

AppLovin Stock Drops After Q1 Earnings Beat as Wall Street Questions What Comes Next
Next Story

AppLovin Stock Drops After Q1 Earnings Beat as Wall Street Questions What Comes Next

Go toTop